Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy.
Cancer - Breast
Grace Makari-Judson, MD
D’Amour Center for Cancer Care
3350 Main Street
Springfield MA 01199
The purpose of this study is to compare the addition of olaparib after the usual care of chemotherapy, surgery, and radiation.
Non-metastatic breast cancer; ER/PR negative; HER2 negative; BRCA1 or 2 mutation
Rae Lynn Defeo